Pliant Therapeutics Inc. Common Stock (PLRX)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Viewing Pliant as a Graham-style bargain candidate, I start with the numbers and quickly see why the market prices it under a dollar. At the close on 2026-10-13, the stock was $0.97, with a market cap of $59.9M and a price-to-book of 0.41. That looks cheap versus book, but book value is not earning power; it largely reflects cash being spent on a clinical-stage enterprise with no product revenue. In fiscal Q2 2026, the quarter ended 2026-06-30, the company reported no revenue and a net loss of $22.4M, or diluted EPS of -$0.36. In fiscal Q1 2026, ended 2026-03-31, net loss was $20.0M, or -$0.32. Fiscal 2025 produced a net loss of $149.3M, or -$2.43 diluted EPS, after a $210.3M loss in fiscal 2024. This is not a business with a moat; it is an early-stage biotech with a Phase 1a/1b candidate and a discovery platform. Financial health is poor: trailing free cash flow was -$70.9M, a -118.3% FCF yield, Piotroski 0/9, Altman Z-Score -4.88. Yes, debt-to-equity is modest at 0.20, and profit growth of 48.33% suggests losses narrowing, but the company still must fund future trials. The 52-week range of $0.96-$1.95 shows the market has lost confidence. A low price-to-book can be a trap when the assets are cash being consumed. The computed Lynch category is none, because losses occurred in each of the last four years. I would need a much clearer path to an approved product and financing runway before calling this a value investment rather than speculation.

In plain English: Pliant Therapeutics is a small biotech company with no product on the market; it is testing a cancer drug and losing money. The business looks weak because it has no revenue and spends a lot of cash, but the stock price is very low compared with its accounting value. That low price may reflect high risk rather than a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer